Prevalence of autoantibodies against 3-DG-glycated H2A protein in type 2 diabetes
- 50 Downloads
Advanced glycation end-products (AGEs) have been found to be critically involved in initiation or progression of diabetes secondary complications (nephropathy, retinopathy, neuropathy, and angiopathy). Various hyper-glycating carbonyl compounds such as 3-deoxyglucosone (3-DG) are produced in pathophysiological conditions that form AGEs in high quantity both in vivo and in vitro. In the first stage of this study, we glycated histone H2A protein by 3-DG, and the results showed the formation of various intermediates and AGEs as well as structural changes in the protein. In the second stage, we studied the immunogenicity of native and 3-DG-glycated H2A protein in female rabbits. The modified H2A was highly immunogenic, eliciting high titer immunogen-specific antibodies, while the unmodified form was almost nonimmunogenic. Antibodies against standard carboxymethyllysine (CML) and pentosidine were detected in the immunized female rabbits, which demonstrates the immunogenic nature of AGEs (CML and pentosidine) as well. The results show both structural perturbation and AGEs have the capacity of triggering the immune system due to the generation of neoepitopes that render the molecule immunogenic. This study shows the presence of autoantibodies against 3-DG-modified H2A, CML, and pentosidine in the sera of type 2 diabetes patients having secondary complications. Autoantibodies against damaged H2A and AGEs may be significant in the assessment of initiation/progression of secondary complications in type 2 diabetes mellitus patients or may be used as a marker for early detection of secondary complications in diabetes.
Keywordsadvanced glycation end-products anti-AGE antibodies ELISA autoantibodies immunogenicity type 2 diabetes
advanced glycation end-products
Unable to display preview. Download preview PDF.
- 5.Bucala, R., Cerami, A., and Vlassara, H. (1995) Advanced glycosylation end products in diabetic complications, Diabetes Rev., 3, 258–268.Google Scholar
- 7.Uribarri, J., Cai, W., Peppa, M., Goodman, S., Ferucci, L., Striker, G., and Vlassara, H. (2007) Circulating glycotoxins and dietary advanced glycation end products: two links to inflammatory response, oxidative stress and aging, J. Gerontol. A Biol. Sci. Med. Sci., 62, 427–433.CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Wolffe, A. (1998) Chromatin. Structure and Function, Academic Press, San Diego, p. 447.Google Scholar
- 25.Ansari, N. A., and Dash, D. (2013) Biochemical studies on methylglyoxal mediated glycated histones: implications for presence of serum antibodies against the glycated histones in patients with type 1 diabetes mellitus, ISRN Biochem., 198065.Google Scholar
- 32.Ashraf, J. M., Ahmad, S., Rabbani, G., Hasan, Q., Jan, A. T., Lee, E. J., and Choi, I. (2015) 3-Deoxyglucosone: a potential glycating agent accountable for structural alteration in H3 histone protein through generation of different AGEs, PLoS One, 10, e0116804.CrossRefPubMedPubMedCentralGoogle Scholar
- 38.Ikeda, K., Higashi, T., Sano, H., Jinnouchi, Y., Yoshida, M., Araki, T., Ueda, S., and Horiuchi, S. (1996) Nε-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction, Biochemistry, 35, 8075–8083.CrossRefPubMedGoogle Scholar
- 41.Ahmad, S., Moinuddin, Habib, S., Shahab, U., Alam, K., and Ali, A. (2014) Autoimmune response to AGE modified human DNA: implications in type 1 diabetes mellitus, J. Clin. Trans Endo, 1, 66–72.Google Scholar
- 42.Ahmad, S. (2014) Immunogenicity of DNA damage by free radicals and carbonyls: a probable biomarker for the autoimmune diseases, J. Immun. Res., 1, 2.Google Scholar
- 43.Shahab, U., Tabrez, S., Khan, M. S., Akhter, F., Khan, M. S., Saeed, M., Ahmad, K., Srivastava, A. K., and Ahmad, S. (2014) Immunogenicity of DNA-advanced glycation end product fashioned through glyoxal and arginine in the presence of Fe3+: its potential role in prompt recognition of diabetes mellitus autoantibodies, Chem. Biol. Int., 219, 229–240.CrossRefGoogle Scholar